NO20023828L - Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer - Google Patents
Pyrimidin-4-on derivater som LDL-PLA2 inhibitorerInfo
- Publication number
- NO20023828L NO20023828L NO20023828A NO20023828A NO20023828L NO 20023828 L NO20023828 L NO 20023828L NO 20023828 A NO20023828 A NO 20023828A NO 20023828 A NO20023828 A NO 20023828A NO 20023828 L NO20023828 L NO 20023828L
- Authority
- NO
- Norway
- Prior art keywords
- ldl
- pyrimidin
- derivatives
- pla2 inhibitors
- pla2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0003636A GB0003636D0 (en) | 2000-02-16 | 2000-02-16 | Novel compounds |
GB0101437A GB0101437D0 (en) | 2001-01-19 | 2001-01-19 | Novel Compounds |
PCT/EP2001/001515 WO2001060805A1 (en) | 2000-02-16 | 2001-02-13 | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20023828D0 NO20023828D0 (no) | 2002-08-13 |
NO20023828L true NO20023828L (no) | 2002-09-30 |
NO324691B1 NO324691B1 (no) | 2007-12-03 |
Family
ID=26243663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20023828A NO324691B1 (no) | 2000-02-16 | 2002-08-13 | Pyrimidin-4-on derivater, farmasoytisk sammensetning inneholdende en slik forbindelse, samt anvendelse av forbindelsene |
Country Status (32)
Country | Link |
---|---|
US (10) | US20020103213A1 (no) |
EP (2) | EP1263740B1 (no) |
JP (1) | JP4095804B2 (no) |
KR (1) | KR100781425B1 (no) |
CN (1) | CN1179952C (no) |
AR (1) | AR030190A1 (no) |
AT (2) | ATE437862T1 (no) |
AU (2) | AU3546601A (no) |
BG (1) | BG66014B1 (no) |
BR (1) | BRPI0108396B1 (no) |
CA (1) | CA2400554C (no) |
CO (1) | CO5271661A1 (no) |
CY (2) | CY1105649T1 (no) |
CZ (1) | CZ304450B6 (no) |
DE (2) | DE60139429D1 (no) |
DK (2) | DK1263740T3 (no) |
ES (2) | ES2330552T3 (no) |
GC (1) | GC0000221A (no) |
HK (1) | HK1053466A1 (no) |
HU (1) | HU229479B1 (no) |
IL (2) | IL151236A (no) |
MX (1) | MXPA02008062A (no) |
MY (1) | MY135732A (no) |
NO (1) | NO324691B1 (no) |
NZ (1) | NZ520752A (no) |
PL (1) | PL209824B1 (no) |
PT (2) | PT1686119E (no) |
SI (2) | SI1263740T1 (no) |
SK (1) | SK287296B6 (no) |
TW (1) | TW550259B (no) |
UA (1) | UA73762C2 (no) |
WO (1) | WO2001060805A1 (no) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2330552T3 (es) | 2000-02-16 | 2009-12-11 | Smithkline Beecham Plc | Derivados de pirimidin-5-ona como inhibidores de ldl-pla2. |
GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
EP1326830A1 (en) * | 2000-10-20 | 2003-07-16 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
GB0119795D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel process |
GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
GB0127140D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127141D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham Plc | Novel compounds |
GB0127143D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
WO2003057671A1 (fr) * | 2001-12-28 | 2003-07-17 | Takeda Chemical Industries, Ltd. | Compose biaryle et son utilisation |
US6939863B2 (en) | 2002-01-04 | 2005-09-06 | Wei-Jan Chen | Prevention of atherosclerosis and restenosis |
GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
US20050227974A9 (en) * | 2002-08-01 | 2005-10-13 | Euro-Celtique S.A. | Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
JP4366122B2 (ja) * | 2003-06-24 | 2009-11-18 | 日立オムロンターミナルソリューションズ株式会社 | 紙葉類搬送装置 |
GB0320522D0 (en) * | 2003-09-02 | 2003-10-01 | Glaxo Group Ltd | Formulation |
CN1875002B (zh) | 2003-11-05 | 2011-08-03 | 霍夫曼-拉罗奇有限公司 | 作为ppar激动剂的苯基衍生物 |
WO2005113797A2 (en) | 2004-04-16 | 2005-12-01 | Glaxo Group Limited | METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
JP4906715B2 (ja) | 2004-05-08 | 2012-03-28 | ニューロジェン・コーポレーション | 4,5−ジ置換−2−アリールピリミジン類 |
DE102004061005A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Cycloalkyl-1,2,4-triazin-5(2H)-one |
US7705005B2 (en) * | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
US20080090852A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US20080090851A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
KR101563753B1 (ko) * | 2007-05-11 | 2015-10-27 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 피부 궤양의 치료 방법 |
MX2009012188A (es) | 2007-05-11 | 2010-02-24 | Univ Jefferson | Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos. |
US8637524B2 (en) | 2009-07-28 | 2014-01-28 | Auspex Pharmaceuticals, Inc | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 |
UY33388A (es) * | 2010-05-17 | 2011-12-01 | Glaxo Group Ltd | Nuevos procesos para la preparacion de compuestos de pirimidinona |
ES2611150T3 (es) | 2010-06-18 | 2017-05-05 | The Whitehead Institute For Biomedical Research | PLA2G16 como diana para compuestos antivirales |
CN104478812A (zh) * | 2010-12-06 | 2015-04-01 | 葛兰素集团有限公司 | 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物 |
WO2012076435A1 (en) | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 |
EP2649050A4 (en) * | 2010-12-06 | 2014-04-23 | Glaxo Group Ltd | LINKS |
EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
CN102643269B (zh) * | 2011-02-21 | 2014-07-23 | 天津药物研究院 | 一类含吡唑结构的磷脂酶a2抑制剂及用途 |
CN103476414B (zh) * | 2011-03-16 | 2015-07-08 | 中国科学院上海药物研究所 | 季铵盐类化合物、其制备方法、药物组合物及用途 |
WO2012129792A1 (zh) * | 2011-03-30 | 2012-10-04 | 中国科学院上海药物研究所 | 嘧啶酮类化合物、其制备方法及药物组合物和用途 |
WO2013000267A1 (zh) | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
EP2739627A4 (en) | 2011-07-27 | 2015-01-21 | Glaxo Group Ltd | 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2 |
JP2014521625A (ja) | 2011-07-27 | 2014-08-28 | グラクソ グループ リミテッド | 二環式ピリミドン化合物 |
CN103827116B (zh) * | 2011-07-27 | 2016-08-31 | 葛兰素集团有限公司 | 用作LP-PLA2抑制剂的2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮化合物 |
BR112015017768A2 (pt) | 2013-01-25 | 2017-07-11 | Glaxosmithkline Ip Dev Ltd | compostos |
RU2015135824A (ru) | 2013-01-25 | 2017-03-03 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 |
EP2948452B1 (en) | 2013-01-25 | 2017-08-09 | GlaxoSmithKline Intellectual Property Development Limited | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
WO2015087239A1 (en) | 2013-12-11 | 2015-06-18 | Ranbaxy Laboratories Limited | Processes for the preparation of darapladib and its intermediates |
WO2015092687A2 (en) | 2013-12-17 | 2015-06-25 | Ranbaxy Laboratories Limited | Process for the purification of darapladib |
WO2015114479A1 (en) | 2014-01-28 | 2015-08-06 | Ranbaxy Laboratories Limited | Crystalline forms of darapladib oxalate, adipate, succinate, phosphate, sulphate, fumaratetartrate, nitrate and borate |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
AU2015308350B2 (en) | 2014-08-29 | 2020-03-05 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
CN105777653A (zh) * | 2014-12-26 | 2016-07-20 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物 |
CN104840963B (zh) * | 2015-05-26 | 2018-02-16 | 河北东康生物科技有限公司 | 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用 |
US10464896B2 (en) * | 2015-06-11 | 2019-11-05 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
BR112018012112A2 (pt) * | 2015-12-16 | 2018-12-04 | Bristol-Myers Squibb Company | heteroaril-hidroxipirimidinonas como agonistas do receptor apj |
US10878307B2 (en) * | 2016-12-23 | 2020-12-29 | Microsoft Technology Licensing, Llc | EQ-digital conversation assistant |
EP3687980B1 (en) | 2017-09-26 | 2022-01-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Radiolabeled darapladib, analogs thereof and their use as imaging compounds |
CN110746445B (zh) * | 2019-10-16 | 2021-03-16 | 深圳海关食品检验检疫技术中心 | 一种头孢哌酮氘代内标物的制备方法 |
MX2022005615A (es) | 2019-11-09 | 2022-07-27 | Shanghai Simr Biotechnology Co Ltd | Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceutica y uso del mismo. |
CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
EP4257133A1 (en) | 2022-04-05 | 2023-10-11 | Institut Pasteur | Oxo-azaheterocyclic derivatives for use in the treatment of malaria |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981252A (en) | 1993-06-25 | 1999-11-09 | Smithkline Beecham | Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
DE69434609T2 (de) * | 1993-10-06 | 2006-09-21 | Icos Corp., Bothell | Acethylhydrolase des Plättchen aktivierenden Faktors |
GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
HUT77089A (hu) | 1994-12-22 | 1998-03-02 | Smithkline Beecham Plc. | Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények |
CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
AU708032B2 (en) | 1995-07-01 | 1999-07-29 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis |
CA2233300A1 (en) | 1995-09-29 | 1997-04-10 | Christopher Donald Southan | A paf-acetylhydrolase and use in therapy |
EP0865429A1 (en) | 1995-12-08 | 1998-09-23 | Smithkline Beecham Plc | Azetidinone compounds for the treatment of atherosclerosis |
WO1997021675A1 (en) | 1995-12-08 | 1997-06-19 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
HUP9901359A3 (en) | 1996-04-26 | 2000-03-28 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them |
GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
US6417192B1 (en) * | 1997-11-06 | 2002-07-09 | Smithkline Beecham P.L.C. | Pyrimidinone compounds and pharmaceutical compositions containing them |
ATE251613T1 (de) | 1998-08-21 | 2003-10-15 | Smithkline Beecham Plc | Pyrimidinonderivate zur behandlung von atheroscleros |
GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
DK1175408T3 (da) * | 1999-05-01 | 2005-04-11 | Smithkline Beecham Plc | Pyrimidinonforbindelser |
GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
ES2330552T3 (es) | 2000-02-16 | 2009-12-11 | Smithkline Beecham Plc | Derivados de pirimidin-5-ona como inhibidores de ldl-pla2. |
GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
GB0024808D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
-
2001
- 2001-02-13 ES ES06075890T patent/ES2330552T3/es not_active Expired - Lifetime
- 2001-02-13 DK DK01907522T patent/DK1263740T3/da active
- 2001-02-13 HU HU0204410A patent/HU229479B1/hu not_active IP Right Cessation
- 2001-02-13 AU AU3546601A patent/AU3546601A/xx active Pending
- 2001-02-13 AU AU2001235466A patent/AU2001235466B2/en not_active Ceased
- 2001-02-13 EP EP01907522A patent/EP1263740B1/en not_active Expired - Lifetime
- 2001-02-13 CA CA002400554A patent/CA2400554C/en not_active Expired - Fee Related
- 2001-02-13 PT PT06075890T patent/PT1686119E/pt unknown
- 2001-02-13 UA UA2002097389A patent/UA73762C2/uk unknown
- 2001-02-13 BR BRPI0108396-1A patent/BRPI0108396B1/pt not_active IP Right Cessation
- 2001-02-13 SK SK1177-2002A patent/SK287296B6/sk not_active IP Right Cessation
- 2001-02-13 PL PL357382A patent/PL209824B1/pl unknown
- 2001-02-13 ES ES01907522T patent/ES2267714T3/es not_active Expired - Lifetime
- 2001-02-13 MX MXPA02008062A patent/MXPA02008062A/es active IP Right Grant
- 2001-02-13 AT AT06075890T patent/ATE437862T1/de active
- 2001-02-13 NZ NZ520752A patent/NZ520752A/en not_active IP Right Cessation
- 2001-02-13 DE DE60139429T patent/DE60139429D1/de not_active Expired - Lifetime
- 2001-02-13 AT AT01907522T patent/ATE333446T1/de active
- 2001-02-13 SI SI200130614T patent/SI1263740T1/sl unknown
- 2001-02-13 CZ CZ2002-2768A patent/CZ304450B6/cs not_active IP Right Cessation
- 2001-02-13 DE DE60121550T patent/DE60121550T2/de not_active Expired - Lifetime
- 2001-02-13 SI SI200130941T patent/SI1686119T1/sl unknown
- 2001-02-13 EP EP06075890A patent/EP1686119B1/en not_active Expired - Lifetime
- 2001-02-13 WO PCT/EP2001/001515 patent/WO2001060805A1/en active Application Filing
- 2001-02-13 KR KR1020027010662A patent/KR100781425B1/ko not_active IP Right Cessation
- 2001-02-13 JP JP2001560190A patent/JP4095804B2/ja not_active Expired - Fee Related
- 2001-02-13 DK DK06075890T patent/DK1686119T3/da active
- 2001-02-13 PT PT01907522T patent/PT1263740E/pt unknown
- 2001-02-13 CN CNB01806521XA patent/CN1179952C/zh not_active Expired - Fee Related
- 2001-02-14 AR ARP010100659A patent/AR030190A1/es not_active Application Discontinuation
- 2001-02-14 MY MYPI20010671A patent/MY135732A/en unknown
- 2001-02-14 GC GCP20011178 patent/GC0000221A/en active
- 2001-02-14 US US09/782,930 patent/US20020103213A1/en not_active Abandoned
- 2001-02-15 CO CO01011957A patent/CO5271661A1/es active IP Right Grant
- 2001-02-15 TW TW090103332A patent/TW550259B/zh not_active IP Right Cessation
-
2002
- 2002-08-13 IL IL151236A patent/IL151236A/en not_active IP Right Cessation
- 2002-08-13 NO NO20023828A patent/NO324691B1/no not_active IP Right Cessation
- 2002-08-26 BG BG107034A patent/BG66014B1/bg unknown
-
2003
- 2003-02-03 US US10/357,238 patent/US6649619B1/en not_active Expired - Lifetime
- 2003-06-09 HK HK03104052A patent/HK1053466A1/xx not_active IP Right Cessation
- 2003-10-27 US US10/694,561 patent/US7153861B2/en not_active Expired - Fee Related
-
2006
- 2006-10-06 CY CY20061101441T patent/CY1105649T1/el unknown
- 2006-11-17 US US11/561,035 patent/US7470694B2/en not_active Expired - Fee Related
- 2006-11-21 US US11/561,926 patent/US7638520B2/en not_active Expired - Fee Related
-
2007
- 2007-03-15 IL IL181957A patent/IL181957A0/en unknown
-
2009
- 2009-01-06 US US12/349,086 patent/US7652019B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/372,837 patent/US20090170877A1/en not_active Abandoned
- 2009-10-12 CY CY20091101045T patent/CY1109484T1/el unknown
-
2010
- 2010-02-18 US US12/707,838 patent/US20100144765A1/en not_active Abandoned
-
2011
- 2011-12-02 US US13/309,941 patent/US8871775B2/en not_active Expired - Fee Related
-
2014
- 2014-10-24 US US14/522,870 patent/US9266841B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20023828L (no) | Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer | |
DK1289985T3 (da) | Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer | |
NO20021239L (no) | Pteridinoner som kinase-inhibitorer | |
NO20030055L (no) | Colchinolderivater som angiogenese inhibitorer | |
NO20030867D0 (no) | Hydroksamderivater anvendelig som deacetylaseinhibitorer | |
DK1337527T3 (da) | Indolylmaleinimidderivater som proteinkinase C-inhibitorer | |
DK1244647T3 (da) | Quinzolinderivater som VIGF-inhibitorer | |
DK1585749T3 (da) | Diazepinoindol-derivater som kinaseinhibitorer | |
NO20021329D0 (no) | Kinaseinhibitorer som terapeutiske midler | |
NO20015065D0 (no) | Pyrazolobenzodiazepiner som CDK2-inhibitorer | |
NO20014642L (no) | Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer | |
NO20033618L (no) | Ftalayinon-piperidino-derivater som PDE-4-inhibitorer | |
NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
DE60119492D1 (de) | Purinderivate | |
NO20050665L (no) | Pyrrolidonderivater som MAOE inhibitoere | |
DK1140840T3 (da) | omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer | |
DE60103537D1 (de) | Purinderivate | |
AR028575A1 (es) | Derivados de pirrolopiridinona utiles como inhibidores de fosfodiesterasa | |
NO20024997D0 (no) | 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer | |
DK1226143T3 (da) | Imidazopyridinderivater som phosphodiesterase VII-inhibitorer | |
NO20035728L (no) | Pyrrolopyrimidiner som proteinkinaseinhibitorer | |
NO20016201D0 (no) | Tienopyrimidiner som fosfodiesteraseinhibitorer | |
DK1534707T3 (da) | Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer | |
NO20021959D0 (no) | Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer | |
DK1222193T3 (da) | Imidazolderivater som phosphodiesterase VII-inhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |